Medtronic stock raises fiscal 2027 guidance after strong quarter
Published on 10/05/2026 at 15:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Medtronic stock (ISIN IE00BTN1Y115) was last at USD 86.38 on the NYSE on October 2, 2026, while management raised its fiscal 2027 outlook after revenue reached USD 9.76 billion in the first quarter. According to Yahoo Finance on October 2, 2026, Medtronic lifted its organic revenue growth forecast to 7.25%-7.75% from 6.75%-7.25% and set adjusted EPS guidance at USD 5.94-6.00.
Guidance moves above prior range
The fiscal 2027 first-quarter revenue figure represented a 13.7% year-over-year increase, according to Yahoo Finance. Adjusted diluted EPS rose 15.1% to USD 1.45, while GAAP EPS increased 40.7% to USD 1.14 from USD 0.81 in the year-earlier quarter.
The quarter also beat the consensus comparison published by MarketBeat: adjusted EPS of USD 1.45 exceeded the USD 1.39 estimate, while revenue of USD 9.76 billion topped the USD 9.55 billion forecast. The extra fiscal week contributed USD 570 million to revenue, making the 13.7% growth rate stronger than the underlying recurring run rate.
Consensus target sits above quote
MarketScreener identifies Medtronic with ISIN IE00BTN1Y115 and reports a Buy mean consensus from 28 analysts. Its average target is USD 104.83, with a USD 85.00 low and a USD 121.00 high, compared with a last close of USD 89.30 in the page data.
Using the October 2 NYSE price of USD 86.38, the MarketScreener average target of USD 104.83 lies 21.4 percent above the price. The gap is a valuation signal rather than a forecast from this article, and the low target of USD 85.00 shows that analyst views still include a level below the reference price.
Growth must offset mature scale
Medtronic's business spans cardiovascular care, medical surgery, neuroscience and diabetes technology, giving the group several sources of device revenue. The latest quarter showed the benefit of that breadth, but the additional selling week makes the reported growth rate a demanding comparison for later quarters.
The central test is whether the higher fiscal 2027 ranges persist after that calendar effect fades. For investors, the combination of adjusted EPS guidance at USD 5.94-6.00 and a 13.7% reported revenue increase makes execution in the next reported quarter more important than the headline valuation alone.
NYSE quote remains below yearly high
Medtronic stock was last at USD 86.38 on the NYSE on October 2, 2026 at 4:00 p.m. ET, down 0.07 percent from the prior session. The share traded within a 52-week range of USD 73.31 to USD 106.33, while market capitalization stood at USD 110.6 billion and volume reached 34,596,650 shares.
Medtronic stock key facts
- Company: Medtronic plc
- ISIN: IE00BTN1Y115
- Ticker: MDT
- Trading venue: NYSE
- Price (as of October 2, 2026, 4:00 p.m. ET): USD 86.38
- Market capitalization: USD 110.6 billion (as of October 2, 2026)
- 52-week range: USD 73.31-106.33 (as of October 2, 2026)
- Sector / Industry: Healthcare / Medical Devices
- Index membership: S&P 500
